Cisapride

CAS No:
81098-60-4 Category:
  • #LGM Pharma is a Cisapride CAS# 81098-60-4 API supplier distributor based in the USA. Inquire about DMF, cGMP, price, availability, delivery, purity, and more.
  • #Questions? Call our customer API support number 1-(800)-881-8210.
  • #LGM Pharma offers this active ingredient but not the finished dosage forms.

Product Details:

  • CAS No: 81098-60-4
  • AHFC code:
  • Synonyms:
  • ATC Code: A03FA02
  • Chemical Formula:
  • Molecular Weight: 465.945
  • Assay/Purity: Typically NLT 98%
  • DrugBank: DB00604 (APRD00454)
  • SMILES: CO[C,H]1CN(CCCOC2=CC=C(F)C=C2)CC[C,H]1NC(=O)C1=CC(Cl)=C(N)C=C1OC
  • InChl: DCSUBABJRXZOMT-IRLDBZIGSA-N
  • PubChem: 2769
  • IUPAC: 4-amino-5-chloro-N-[(3S,4R)-1-[3-(4-fluorophenoxy)propyl]-3-methoxypiperidin-4-yl]-2-methoxybenzamide

Additional Details

Indication:
For the symptomatic treatment of adult patients with nocturnal heartburn due to gastroesophageal reflux disease.
Pharmacodynamics:
Cisapride is a parasympathomimetic which acts as a serotonin 5-HT4 agonist. Stimulation of the serotonin receptors increases acetylcholine release in the enteric nervous system. Cisapride stimulates motility of the upper gastrointestinal tract without stimulating gastric, biliary, or pancreatic secretions. Cisapride increases the tone and amplitude of gastric (especially antral) contractions, relaxes the pyloric sphincter and the duodenal bulb, and increases peristalsis of the duodenum and jejunum resulting in accelerated gastric emptying and intestinal transit. It increases the resting tone of the lower esophageal sphincter. It has little, if any, effect on the motility of the colon or gallbladder. Cisapride does not induce muscarinic or nicotinic receptor stimulation, nor does it inhibit acetylcholinesterase activity.
Mode of Action:
Cisapride acts through the stimulation of the serotonin 5-HT_ receptors which increases acetylcholine release in the enteric nervous system (specifically the myenteric plexus). This results in increased tone and amplitude of gastric (especially antral) contractions, relaxation of the pyloric sphincter and the duodenal bulb, and increased peristalsis of the duodenum and jejunum resulting in accelerated gastric emptying and intestinal transit.
Metabolism:
Hepatic. Extensively metabolized via cytochrome P450 3A4 enzyme.
Toxicity:
General Reference:
Pearce RE, Gotschall RR, Kearns GL, Leeder JS: Cytochrome P450 Involvement in the biotransformation of cisapride and racemic norcisapride in vitro: differential activity of individual human CYP3A isoforms. Drug Metab Dispos. 2001 Dec;29(12):1548-54. Pubmed
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

API’s From Quality Manufacturers:

  • Cost effective materials based on specific requirements
  • Small quantities for initial research and larger development quantities towards product commercialization

 

  • Technical packages, letters of access to filed DMFs
  • Complete assistance in any regulatory filings
  • Top quality GMP certified manufacturers
  • Have necessary regulatory credentials

 

Related YouTube Videos